Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010)
Alnylam Pharmaceuticals (ALNY) reported Current Deferred Tax Assets of $1.9 million for Q3 2010, little changed quarter-over-quarter from $1.9 million in Q2 2010.
Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010) Analysis & Trends
Alnylam Pharmaceuticals has reported Current Deferred Tax Assets for 2 years, with the latest figure at $1.9 million in Q3 2010.
- For the quarter ending Q3 2010, Current Deferred Tax Assets changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Sep 2010 stood at $1.9 million (changed N/A YoY), and the FY2009 full-year result was $1.9 million, changed N/A from the prior year.
- Current Deferred Tax Assets for Q3 2010 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
- The five-year high for Current Deferred Tax Assets was $1.9 million in Q3 2010, with the low at $1.9 million in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | 1.94 Mn |
| Sep 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 1.94 Mn |
| Dec 31, 2009 | 1.94 Mn |
| Dec 31, 2009 | 1.94 Mn |